Paper17545598
T-lymphokine-activated killer cell-originated protein kinase functions as a positive regulator of c-Jun-NH2-kinase 1 signaling and H-Ras-induced cell transformation.
Oh SM and 8 others. Cancer Res, 2007. Cited by 58 papers, by iCite.
Cite this record
ConductScience Library. T-lymphokine-activated killer cell-originated protein kinase functions as a positive regulator of c-Jun-NH2-kinase 1 signaling and H-Ras-induced cell transformation. Papers, record 17545598. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17545598
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Transformation, Neoplastic | Major topic |
| Genes, ras | Major topic |
| MAP Kinase Signaling System | Major topic |
| Mitogen-Activated Protein Kinase 8 | Major topic |
| Protein Serine-Threonine Kinases | Major topic |
| Adaptor Proteins, Signal Transducing | |
| Animals | |
| DNA, Complementary | |
| Enzyme Activation | |
| Humans | |
| Melanoma | |
| Mice | |
| Mice, Knockout | |
| Mitogen-Activated Protein Kinase Kinases | |
| Phosphorylation | |
| Swiss 3T3 Cells | |
| Transcription Factor AP-1 | |
| Transfection | |
| Ultraviolet Rays |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA111356 | NCI NIH HHS | United States | R01CA111356 | PubMed and NIH | NIH RePORTER |
| CA27502 | NCI NIH HHS | United States | P01CA027502 | PubMed and NIH | NIH RePORTER |
| CA77646 | NCI NIH HHS | United States | R01CA077646 | PubMed and NIH | NIH RePORTER |
| CA81064 | NCI NIH HHS | United States | R01CA081064 | PubMed and NIH | NIH RePORTER |
| CA88961 | NCI NIH HHS | United States | P01CA088961 | PubMed and NIH | NIH RePORTER |
| R37CA081064 | NIH | NIH RePORTER |
Cited by41
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 58 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42079338 | Advances in T-Lymphokine-activated Killer Cell-originated Protein Kinase Research in Cancer Over the Past Thirty Years. | J Cancer Prev | 2026 | https://conductscience.org/library/papers/42079338 | PubMed |
| 41362722 | The Roles of TOPK in Tumorigenesis and Development: Structure, Mechanisms, Pathways, and Therapeutic Implications. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/41362722 | PubMed |
| 40301429 | Correlation study of PBK/TOPK expression, prognosis, and immune infiltration in breast cancer. | Sci Rep | 2025 | https://conductscience.org/library/papers/40301429 | PubMed |
| 40224460 | Sinomenine Inhibits TOPK To Ameliorate Psoriasiform Dermatitis. | ACS Omega | 2025 | https://conductscience.org/library/papers/40224460 | PubMed |
| 39803648 | Protein tyrosine phosphatase PTPH1 potentiates receptor tyrosine kinase HER2 oncogenesis via a PDZ-coupled and phosphorylation-driven scaffold. | Am J Cancer Res | 2024 | https://conductscience.org/library/papers/39803648 | PubMed |
| 39649886 | Unraveling the role of PBK in glioblastoma: from molecular mechanisms to therapeutic targets. | Ann Med Surg (Lond) | 2024 | https://conductscience.org/library/papers/39649886 | PubMed |
| 35203508 | PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers. | Biomedicines | 2022 | https://conductscience.org/library/papers/35203508 | PubMed |
| 34859058 | Omics- and Pharmacogenomic Evidence for the Prognostic, Regulatory, and Immune-Related Roles of PBK in a Pan-Cancer Cohort. | Front Mol Biosci | 2021 | https://conductscience.org/library/papers/34859058 | PubMed |
| 34227361 | [Affinity chromatography based phosphoproteome research on lung cancer cells and its application]. | Se Pu | 2021 | https://conductscience.org/library/papers/34227361 | PubMed |
| 34066486 | PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34066486 | PubMed |
| 33670114 | PBK/TOPK: A Therapeutic Target Worthy of Attention. | Cells | 2021 | https://conductscience.org/library/papers/33670114 | PubMed |
| 33431797 | PBK phosphorylates MSL1 to elicit epigenetic modulation of CD276 in nasopharyngeal carcinoma. | Oncogenesis | 2021 | https://conductscience.org/library/papers/33431797 | PubMed |
| 33093441 | Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma. | Signal Transduct Target Ther | 2020 | https://conductscience.org/library/papers/33093441 | PubMed |
| 32277233 | Suppression of the solar ultraviolet-induced skin carcinogenesis by TOPK inhibitor HI-TOPK-032. | Oncogene | 2020 | https://conductscience.org/library/papers/32277233 | PubMed |
| 32237067 | PBK attenuates paclitaxel-induced autophagic cell death by suppressing p53 in H460 non-small-cell lung cancer cells. | FEBS Open Bio | 2020 | https://conductscience.org/library/papers/32237067 | PubMed |
| 31985814 | Acetylshikonin suppressed growth of colorectal tumour tissue and cells by inhibiting the intracellular kinase, T-lymphokine-activated killer cell-originated protein kinase. | Br J Pharmacol | 2020 | https://conductscience.org/library/papers/31985814 | PubMed |
| 30898980 | Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase/T-LAK cell-originated protein kinase. | Biosci Rep | 2019 | https://conductscience.org/library/papers/30898980 | PubMed |
| 30356039 | T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics. | Cell Death Dis | 2018 | https://conductscience.org/library/papers/30356039 | PubMed |
| 30292353 | Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors. | Trends Cancer | 2018 | https://conductscience.org/library/papers/30292353 | PubMed |
| 29904102 | Targeting PRPK and TOPK for skin cancer prevention and therapy. | Oncogene | 2018 | https://conductscience.org/library/papers/29904102 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| HRAS | 3265 | PubTator's text mining | https://conductscience.org/library/genes/3265 | NCBI Gene |
| JUN | 3725 | PubTator's text mining | https://conductscience.org/library/genes/3725 | NCBI Gene |
| MAPK8 | 5599 | PubTator's text mining | https://conductscience.org/library/genes/5599 | NCBI Gene |
| MAPK8IP1 | 9479 | PubTator's text mining | https://conductscience.org/library/genes/9479 | NCBI Gene |
| PBK | 55872 | PubTator's text mining | https://conductscience.org/library/genes/55872 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17545598
GET https://conductscience.org/api/papers/v1/17545598/cited_by?page=2